These results indicated that AKR1C1 promotes the oncogenic signaling STAT1 and STAT3 activation and downstream signaling that might contribute to cisplatin-resistance in HNSCC. This evidence concerns the gene AKR1C1 and head and neck squamous cell carcinoma.